SYN1327 acetate
Based on 1 Customer Validation
SYN1327 acetate is a potent monomeric cyclic competitive antagonistic peptide targeting the neonatal Fc receptor (FcRn), with a Kd of 31 nM for human FcRn at pH 6 and a Kd of 170 nM at pH 7.4. SYN1327 acetate competitively binds to the IgG-binding site of FcRn and inhibits the binding of human IgG to FcRn. SYN1327 acetate acts as the monomeric precursor of the dimeric peptide SYN1436 (HY-P11882). SYN1327 acetate can be used in studies related to IgG-mediated autoimmune diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C72H101N19O16S2·xC2H4O2
- Masse moléculaire:1552.82 (free base)
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Activité biologique
SYN1327 acetate exhibits pH-dependent binding to FcRn, with a binding constant of 31 nM at pH 6.0 and 170 nM at pH 7.4[1][2][3].
SYN1327 acetate inhibits the interaction between hIgG and immobilized shFcRn in ELISA-based assays at pH 6 with an IC50 of 570 nM; in FACS-based competition assays, it inhibits the binding of fluorescently labeled hIgG to 293c11 cells expressing hFcRn at pH 6, with an IC50 of 510 nM[2].
SYN1327 acetate potently binds to human and cynomolgus monkey FcRn at pH 6, but its binding affinity for mouse and rat FcRn is approximately 1000-fold weaker, and it only exhibits weak non-specific binding to human HLA-A2[2].
SYN1327 acetate inhibits the interaction between human IgG and human FcRn in in vitro ELISA assays, with an IC50 of 520 nM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Masse moléculaire 1552.82 (free base)
-
Formule C72H101N19O16S2·xC2H4O2
-
SMILES
CC(O)=O.O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](C(C)(SSC[C@@H](C(N)=O)NC2=O)C)C(N[C@@H]([C@H](O)C)C(NCC(N[C@@H](CC3=CNC=N3)C(N[C@@H](CC4=CC=CC=C4)C(NCC(N(C)CC(N(C)[C@@H](CC(C)C)C(N[C@@H](CC5=CC=C(C=C5)O)C(N6[C@H]2CCC6)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C.[x]
-
Sequence
Ac-Arg-Phe-Pen-Thr-Gly-His-Phe-Gly-Sar-{NMeLeu}-Tyr-Pro-Cys-NH2 (disulfide bridge:Pen3-Cys13)
-
Sequence Shortening
Ac-RF-Pen-TGHFG-Sar-{NMeLeu}-YPC-NH2 (disulfide bridge:Pen3-Cys13)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)